ADVERTISEMENT



Google       

Home -> Law Blog Directory -> Patent Law Blogs -> IPBiz

OR PHONE (866) 635-1838 for Bankruptcy Help, (866) 635-6190 for Divorce,
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense

Find a Local Lawyer

Bankruptcy (866) 635-1838
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402

Bookmark

Patent Law

: IPBiz

Novartis makes plans for Diovan going off patent in 2012

By Lawrence B. Ebert, Esq.

ADVERTISEMENTS
MarketWatch reports: Novartis is working on several drugs that will combine its new heart medicine Rasilez and another drug in a single pill to prepare for the expected loss of revenue when the patent of its best-selling drug Diovan will expire in four years, the Swiss drugmaker said November 19, 2008.

Diovan is Novartis's proprietary name for Valsartan, which is an angiotensin II receptor antagonist (more commonly called an "ARB", which stands for Angiotensin Receptor Blocker).

Wikipedia notes

Whether Angiotensin II Receptor Blockers may or may not increase the risk of myocardial infarction [MI] was announced in the BMJ and was more recently debated in the medical journal of the American Heart Association. To date, there is no consensus on whether ARBs have a tendency to increase MI, but there is also no substantive evidence to indicate that ARBs are able to reduce MI.

Of a Diovan combination drug, Wikipedia notes

Diovan HCT contains a combination of Valsartan and hydrochlorothiazide but, unlike Diovan, is only indicated for hypertension, not for CHF or post-MI.

Full post as published by IPBiz on November 19, 2008 (boomark / email).

Bloggers, promote your law blog by nominating your blog for inclusion in USLaw.com's Law Blog Directory and RSS Reader. Benefits described.
Related Law Articles

Pre-paid Leagal Services
What are Prepaid Legal Benefit Plans

Lawsuits and Settlements

T-mobile data plans, T-mobile, t-mobile phones
T-Mobile Faces Class Action over Limited Unlimited Data Plans

Virgin Atlantic Flight
Makes Emergency Landing

Zantac Patent
GlaxoSmithKline and Cypress Pharmaceutical settle patent infringement dispute.

Female Sales Reps Win Gender Case Against Novartis
Female Sales Reps Win Gender Case Against Novartis

Soliris Patent
Alexion Pharmaceuticals Inc. agrees to pay the Oklahoma Medical Research Foundation a $10 million patent infringement settlement.

Medicaid Fraud
GSK and Novartis Face $800 Million in Penalties

Related Searches

























































































































US Law
#1 Online Legal Resource













Your Blog Subscriptions
Subscribe to blogs

10,000+ Law Job Listings
Lawyer . Police . Paralegal . Etc
Earn a law-related degree
Are you the author of this blog? Adding USLaw.com to your Blogroll increases relevance. You qualify to display a USLaw Network badge.
Suggest changes to this blog's description or nominate another for inclusion. Register for updates.


Practice Area
Zip Code:

Contact a Lawyer Now!






0.0153 secs (new cache)